Imunon reports Phase 2 MRD data for IMNN-001 in ovarian cancer

July 21, 2026 9:00 AM

Imunon, Inc. (Nasdaq: IMNN) announced preliminary data from its ongoing Phase 2 minimal residual disease (MRD) translational clinical trial of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found